Research Article

Prevalence and Factors Associated with Rifampicin Resistant Pulmonary Tuberculosis among Presumptive Patients in Kano State, Nigeria

Mohammad A.B1*, Ibrahim, A.2, Maifada A I3, Balogun M S4, Mohammed, Y.5, Fagge H S6, Iliya S7, Aminu, A. I.8, Mukhtar, M.D.9
1 North West Zonal Tuberculosis Reference Laboratory, Department of Medical Microbiology, Aminu Kano Teaching Hospital, Kano, Nigeria.
2 Department of Microbiology, Faculty of Science, Kaduna State University, Kaduna
3 National Tuberculosis and Leprosy Training Centre, Saye, Zaria, Kaduna State, Nigeria.
4 Nigeria Field Epidemiology and Laboratory Training Programme, African Field Epidemiology Network, Abuja, Nigeria.
5 Department of Medical Microbiology and Parasitology, Faculty of Clinical Sciences, Bayero University Kano, P.M.B. 3011.
6 Infectious Disease Hospital, Ministry of Health, Kano, Kano State, Nigeria.
7 Department of Biological Sciences School of Pure and Applied Sciences, Mount Kenya University, Thika, Kenya.
8 Department of Microbiology, Faculty of Life Sciences, Bayero University, Kano Nigeria.
9 Department of Science Laboratory Technology, School of Technology, Kano state polytechnic, Matan-fada Road, PMB 3348, Kano State, Nigeria
* Corresponding author: mohammadab@nsmjournal.org.ng
Published: Jun, 2021
DOI: 10.67614/njm.2021.q86ixeqm
Pages: 5460-5466

Abstract

Rifampicin-resistant tuberculosis (TB) is an emerging problem of great importance to public  health worldwide and together with multidrug-resistant TB causes higher mortality rates than drug sensitive tuberculosis. Data regarding drug-resistance and risk factors associated with rifampicin resistant  from Kano are lacking. The study therefore, determined the prevalence and risk factors associated with  rifampicin-resistant tuberculosis (RR-TB) in Kano State, Nigeria. A one-year retrospective study was  conducted among tuberculosis patients attending Direct Observed Treatment Short-course centers  equipped with GeneXpert facilities in Kano State, Nigeria from January 2019 to December, 2019.  Pulmonary and extra-pulmonary samples were analyzed using Xpert MTB/RIF assay (Cepheid,  GeneXpert, USA). The data was collected from the Xpert MTB/RIF assay registers and patient’s folder.  Data generated were analyzed using Chi-square and results were presented in tables. Out of 55,021  samples analyzed, 111 (0.2%) had rifampicin-resistant tuberculosis. There was significance relationship  between socio-demographic characteristics (gender, age groups and marital status), prevalence and  transmission dynamic of rifampicin resistant among the studied subject in the study area (Odds Ratio [OR]  = 0.37, 2.54, 1.51; p≤0.5). The study confirmed the presence of rifampicin resistant tuberculosis in the  study area. It also identifies the need to strengthen the laboratory capacity for early diagnosis of RR-TB as  well as improvement on availability and accessibility of the services to patients by the relevant authorities  to reduce the disease burden.
   

Keywords

Rifampicin Resistant Pulmonary Tuberculosis

References

  1. Adane, K., Ameni, G., Bekele, S., Abebe, M. and Aseffa, A. (2015). Prevalence and drug resistance profile of Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients attending two public hospitals in East Gojjam zone, northwest Ethiopia. BMC Public Health 15: 572. https://doi.org/10.1186/s12889-015-1933-9.
  2. Adesokan, H. K., Cadmus, E. O., Adeyemi, W. B., Lawal, O., Ogunlade, C. O., Osman, E. Oladeye, O. D., and Cadmus, S. I. B. (2014).Prevalence of previously undetected tuberculosis and underlying risk factors for transmission in a prison setting in Ibadan, South-Western Nigeria. African Journal of Medical Sciences, 43 (Suppl 1): 45-50.
  3. Alavi-Naini, R., Sharifi-Mood, B., and Metanat, M. (2012). Association between tuberculosis and smoking. International journal of high risk behaviors & addiction, 1(2), 71–74. https://doi.org/10.5812/ijhrba.5215.
  4. Alebel, A., Wondemagegn, A. T., Tesema, C, Kibret, G. D., Wagnew, F., Petrucka, P., Arora, A., Ayele, A. D., Alemayehu, M. and Eshetie, S. (2019). Prevalence of diabetes mellitus among tuberculosis patients in Sub-Saharan Africa: a systematic review and meta-analysis of observational studies. BMC Infectious Diseases, 19: 254.
  5. Aminu A.I. (2020). Studies on Some Haematological and Immunological Indices of Tuberculosis Patients.
  6. Aminu, A.I. and Habib, N.I. (2019). Studies on some Immunological Profile of Tuberculosis Patients Infected with Tuberculosis attending Infectious Diseases Hospital, Kano. Bayero Journal of Pure and Applied Sciences (Special Conference Edition), 12 (1): 5-12. DOI: 10.4314/bajopas.v12i1.2S.
  7. Aminu, A.I. and Tukur, A.D. (2016). Detection of multidrug resistant tuberculosis (MDR-TB) among Rifampicin-resistant TB patients using line probe assay (LPA) in Kano, Nigeria. Bayero Journal of Pure and Applied Sciences, 9 (2): 1-8. DOI: 10.4314/bajopas.v9i2.1.
  8. Ariyothai, N., Podhipak, A., Akarasewi, P., Tornee, S., Smithtikarn, S. and Thongprathum, P. (2004).Cigarette smoking and its relation to pulmonary tuberculosis in adults. Southeas Asian Journal of Tropical Medicine and Public Health, 35 (1): 219-227. PMID: 15272772.
  9. Bai, K-J., Lee, J-J., Chien, S-T., Suk, CW. and Chiang C-Y. (2016).The Influence of Smoking on Pulmonary Tuberculosis in Diabetic and Non-Diabetic Patients. PLoS ONE 11(6): e0156677. doi:10.1371/journal.pone.0156677.
  10. Davies-Bolorunduo O. F., Nduaga, O. T., Abiodun, A. T., Amuda, B. O., Osuolale, K. A., Atoe K. and Cadmus, S. (2020). Prevalence of Rifampicin Resistance among Presumptive Pulmonary Tuberculosis Patients within Lagos and its Environs in South-Western Nigeria. Nigerian Journal of Microbiology, 34 (1): 5188 - 5196
  11. Federal Ministry of Health, Nigeria (FMOHN)/National Tuberculosis and Leprosy Control programme (NTBLC). (2018). Module for training doctors, nurses, state team and consortium of experts on the clinical and programmatic management of drug resistant tuberculosis. 2nd edition. Abuja.
  12. Geleta, D. A., Megersa, Y. C. Gudeta, O. A. Nkalu, G. T. Debele , M. T. and Tulu, K. D. (2015). Xpert MB/RIF assay for diagnosis of pulmonary tuberculosis in sputum specimens in remote health care facility. BMC Microbiology, 15: 220. doi: 10.1186/s12866-015-0566-6.
  13. Lawal, M. A. Omili, M. Bello, T.O. Onuha, L., Haruna, A. (2009). Tuberculosis in a Nigerian Medium Security Prison. 11 (Supplemental): 1-8.
  14. Mohammad, A. B., Iliyasu, G. and Habib, A. G. (2017). Prevalence and Genetic Determinant of Drug-resistant Tuberculosis among Patients Completing Intensive Phase of Treatment in a Tertiary Referral Center in Nigeria. International Journal Mycobacteriology, 6 (1): 47-51. DOI: 10.4103/2212-5531.201883
  15. Onyedum, C. C., Alobu, I. and Ukwaja, K. N. (2017). Prevalence of drug-resistant tuberculosis in Nigeria: A systematic review and meta-analysis. PLoS ONE, 12 (7): e0180096. doi:10.1371/journal.pone.0180096.
  16. Sanders, M., Van Deun, A., Ntakirutimana, D., Masabo, J. P., Rukundo, J., Rigouts, L., Fissette, K., Portaelst, F. (2006). Rifampicin mono-resistant Mycobacterium tuberculosis in Burundi: results of a drug resistance survey. Int J Tuberc Lung Dis. 20 (2): 178-83. PMID: 16499257.
  17. Shao, Y., Zang, D., Xu, Wu., Lu, W., Song, H., Dai, Y. Shen H. and Wang J. (2011). Epidemiology of antituberculosis drug resistance in a chinese population: current situation and challenges ahead. BMC Public Health, 11 (110): 1-8. https://doi.org/10.1186/1471-2458-11-110.
  18. Van Rie, A., Page-Shipp, L., Scott, L., Sanne, I. and Stevens, W. Annelies Van Rie, Liesl Page-Shipp, Lesley Scott, Ian Sanne, Wendy Stevens (2010). Xpert® MTB/RIF for point-of-hope or hope. Expert Review on Molecular Diagnostic, 10 (7): 937-946. doi: 10.1586/erm.10.67.
  19. World Health Organization (WHO) (2016). Global Tuberculosis in Bujumbura, Burundi: results of a drug resistance survey. www.who.int/tb/publications/global_report.
  20. World Health Organization (2017).Global Tuberculosis Report 2017. Document WHO/HTM/TB/2017.23. Geneva, World Health Organization, 2017. http://apps.who.int/iris/bitstream/1965/259366/1/9789241565516-eng.pdf?ua=1.
  21. World Health Organization (WHO), (2018). Author. Global Tuberculosis Report Geneva, Switzerland: World Health Organization. www.who.int/tb/publications/global_report.
How to Cite

A.B, M., A., I., I, M. A., S, B. M., Y., M., S, F. H., S, I., I., A. A., & M.D., M. (2021). Prevalence and Factors Associated with Rifampicin Resistant Pulmonary Tuberculosis among Presumptive Patients in Kano State, Nigeria. Nigerian Journal of Microbiology, 35(1), 5460-5466. https://doi.org/10.67614/njm.2021.q86ixeqm

M. A.B, I. A., M. A. I, B. M. S, M. Y., F. H. S, I. S, A. A. I., and M. M.D., "Prevalence and Factors Associated with Rifampicin Resistant Pulmonary Tuberculosis among Presumptive Patients in Kano State, Nigeria," Nigerian Journal of Microbiology, vol. 35, no. 1, pp. 5460-5466, June 2021. doi: 10.67614/njm.2021.q86ixeqm

Share this article:
Facebook X / Twitter LinkedIn
Download PDF View Full Text (PDF) Back to Articles